Endothelial Insulin and IGF-1 Receptors: When Yes Means NO
Year: 2012
Type: article
Abstract: Cardiovascular (CV) disease is the leading cause ofmorbidity and mortality and a major driver ofhealth care costs in patients with type 2 diabetes.Observational studies suggest that insulin re-sistance and hyperglycemia independently predict athero-sclerosis (1,2). However, recent clinical trials have been disappointing in that intensive glycemic control does not reduce the risk of CV events in individuals with diabetes (3). Consequently, it has been suggested that therapies targeting hyperinsulinemia and/or insulin resistance (e.g., metformin) may lead to CV risk reduction (2). In addition to its meta-bolic actions, insulin has important vascular actions that stimulate endothelial production of nitric oxide (NO), an anti-inflammatory and antiatheroslcerotic molecule (4). In turn, endothelial insulin resistance leads to diminished glu-cose disposal, endothelial dysfunction, and atherosclerosis. Strategies that ameliorate endothelial insulin resistance may simultaneously augment metabolic and vascular actions of
Source: Diabetes
DOI: 10.2337/db12-0654
Authors: Ranganath Muniyappa, James R. Sowers
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2169475722
